Nestlé Acquires Peanut Allergy Treatment Maker, Aimmune Therapeutics

Nestlé has announced that it has completed the acquisition of Aimmune Therapeutics, Inc., the maker of peanut allergy treatment, Palforzia.

Aimmune Therapeutics will be a part of Nestlé Health Science (NHSc) as a stand-alone business unit and continue to operate from Brisbane, California.

In August of this year, Nestlé offered $2 billion (€1.7 billion) to gain full ownership of the California-based biopharmaceutical company.

ESM